208 related articles for article (PubMed ID: 18339846)
1. Prediction of cancer driver mutations in protein kinases.
Torkamani A; Schork NJ
Cancer Res; 2008 Mar; 68(6):1675-82. PubMed ID: 18339846
[TBL] [Abstract][Full Text] [Related]
2. Cancer driver mutations in protein kinase genes.
Torkamani A; Verkhivker G; Schork NJ
Cancer Lett; 2009 Aug; 281(2):117-27. PubMed ID: 19081671
[TBL] [Abstract][Full Text] [Related]
3. Sequence and structure signatures of cancer mutation hotspots in protein kinases.
Dixit A; Yi L; Gowthaman R; Torkamani A; Schork NJ; Verkhivker GM
PLoS One; 2009 Oct; 4(10):e7485. PubMed ID: 19834613
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated mutations are preferentially distributed in protein kinase functional sites.
Izarzugaza JM; Redfern OC; Orengo CA; Valencia A
Proteins; 2009 Dec; 77(4):892-903. PubMed ID: 19626714
[TBL] [Abstract][Full Text] [Related]
5. Identification of constrained cancer driver genes based on mutation timing.
Sakoparnig T; Fried P; Beerenwinkel N
PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
[TBL] [Abstract][Full Text] [Related]
6. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.
Carter H; Chen S; Isik L; Tyekucheva S; Velculescu VE; Kinzler KW; Vogelstein B; Karchin R
Cancer Res; 2009 Aug; 69(16):6660-7. PubMed ID: 19654296
[TBL] [Abstract][Full Text] [Related]
7. Using passenger mutations to estimate the timing of driver mutations and identify mutator alterations.
Youn A; Simon R
BMC Bioinformatics; 2013 Dec; 14():363. PubMed ID: 24330428
[TBL] [Abstract][Full Text] [Related]
8. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.
Buisson R; Langenbucher A; Bowen D; Kwan EE; Benes CH; Zou L; Lawrence MS
Science; 2019 Jun; 364(6447):. PubMed ID: 31249028
[TBL] [Abstract][Full Text] [Related]
9. CanDrA: cancer-specific driver missense mutation annotation with optimized features.
Mao Y; Chen H; Liang H; Meric-Bernstam F; Mills GB; Chen K
PLoS One; 2013; 8(10):e77945. PubMed ID: 24205039
[TBL] [Abstract][Full Text] [Related]
10. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.
Bányai L; Trexler M; Kerekes K; Csuka O; Patthy L
Elife; 2021 Jan; 10():. PubMed ID: 33427197
[TBL] [Abstract][Full Text] [Related]
11. The mutational landscape of phosphorylation signaling in cancer.
Reimand J; Wagih O; Bader GD
Sci Rep; 2013 Oct; 3():2651. PubMed ID: 24089029
[TBL] [Abstract][Full Text] [Related]
12. The mini-driver model of polygenic cancer evolution.
Castro-Giner F; Ratcliffe P; Tomlinson I
Nat Rev Cancer; 2015 Nov; 15(11):680-5. PubMed ID: 26456849
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations in human cancer: insights from resequencing the protein kinase gene family.
Futreal PA; Wooster R; Stratton MR
Cold Spring Harb Symp Quant Biol; 2005; 70():43-9. PubMed ID: 16869737
[TBL] [Abstract][Full Text] [Related]
14. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P; Huang LT; Sakthivel R; Karunagaran D; Gromiha MM
Mutat Res; 2015 Oct; 780():24-34. PubMed ID: 26264175
[TBL] [Abstract][Full Text] [Related]
15. Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers.
Reva B
BMC Genomics; 2013; 14 Suppl 3(Suppl 3):S8. PubMed ID: 23819556
[TBL] [Abstract][Full Text] [Related]
16. Looking beyond drivers and passengers in cancer genome sequencing data.
De S; Ganesan S
Ann Oncol; 2017 May; 28(5):938-945. PubMed ID: 27998972
[TBL] [Abstract][Full Text] [Related]
17. The Damaging Effect of Passenger Mutations on Cancer Progression.
McFarland CD; Yaglom JA; Wojtkowiak JW; Scott JG; Morse DL; Sherman MY; Mirny LA
Cancer Res; 2017 Sep; 77(18):4763-4772. PubMed ID: 28536279
[TBL] [Abstract][Full Text] [Related]
18. QuaDMutEx: quadratic driver mutation explorer.
Bokhari Y; Arodz T
BMC Bioinformatics; 2017 Oct; 18(1):458. PubMed ID: 29065872
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive identification of mutational cancer driver genes across 12 tumor types.
Tamborero D; Gonzalez-Perez A; Perez-Llamas C; Deu-Pons J; Kandoth C; Reimand J; Lawrence MS; Getz G; Bader GD; Ding L; Lopez-Bigas N
Sci Rep; 2013 Oct; 3():2650. PubMed ID: 24084849
[TBL] [Abstract][Full Text] [Related]
20. SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors.
Newberg JY; Black MA; Jenkins NA; Copeland NG; Mann KM; Mann MB
Nucleic Acids Res; 2018 Sep; 46(16):e94. PubMed ID: 29846651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
